RecruitingNCT04120935

ALFAOMEGA Master Observational Trial

A Master Protocol Empowering Precision Research in Colorectal Cancer

Sponsor

IFOM ETS - The AIRC Institute of Molecular Oncology

Enrollment

3,000 participants

Start Date

Oct 15, 2019

Study Type

OBSERVATIONAL

Conditions

Colorectal, Cancer

Summary

AlfaOmega has been designed to streamline the study of the co-evolutionary landscape between tumor and host cells in a cohort of CRC patients, with the aim of understanding how their outcomes can be significantly improved (e.g. reduction of their chance of recurrence and survival improval). This clinical resource for integrative clinical data and sample collection will allow the molecular story-telling of CRC metastatic spread along time and space and the selection of appropriate patients for experimentally-driven trials.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is creating a large research registry of patients with colorectal cancer (CRC). It collects clinical data and tumour tissue samples to study the biology of colorectal cancer and develop better tools for personalised treatment. **You may be eligible if...** - You are 18 years old or older - You have a confirmed diagnosis of colorectal cancer, or there is a strong clinical and imaging suspicion of CRC - Tumour tissue from your diagnosis is available for testing - You are reasonably functional (ECOG performance status below 2) **You may NOT be eligible if...** - You have had another cancer diagnosis (other than non-melanoma skin cancer, early melanoma in situ, or early cervical cancer) in the past 5 years or currently - You cannot comply with the study protocol - You have a known HIV, hepatitis B, hepatitis C, or syphilis infection Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservation

Prospective Observation of standard clinical practice.

Locations(19)

ASL di Biella - Ospedale degli Infermi

Biella, Biella, Italy

IRCCS Istituto Clinico Humanitas

Milan, MI, Italy

Fondazione IRCCS, Istituto Nazionale dei Tumori

Milan, MI, Italy

Istituto Europeo di Oncologia (IEO)

Milan, Mi, Italy

Niguarda Cancer Center - ASST Grande Ospedale Metropolitano Niguarda

Milan, MI, Italy

Istituto Oncologico Veneto (IOV)

Padova, PD, Italy

Ospedale Santa Maria della Misericordia

Perugia, Perugia, Italy

Azienda Ospedaliero Universitaria Pisana

Pisa, Pisa, Italy

AUSL della Romagna - Ospedale Santa Maria delle Croci

Ravenna, Ravenna, Italy

Istituto di Candiolo - IRCCS

Candiolo, Torino, Italy

Azienda Ospedaliero Universitaria San Luigi Gonzaga

Orbassano, Torino, Italy

Ospedale Policlinico San Martino

Genova, Italy

Azienda Ospedaliera Universitaria Luigi Vanvitelli

Naples, Italy

Azienda Ospedaliera Ordine Mauriziano

Torino, Italy

Hospital de Sant Joan Despí Moises Broggi

Barcelona, Barcelona, Spain

Hospital del Mar - Parc de Salut Mar

Barcelona, Spain, Spain

Vall d'Hebron Institute of Oncology (VHIO)

Barcelona, Spain, Spain

INCLIVA - Instituto de Investigatión Sanitaria

Valencia, Spain, Spain

Hospital Moises Broggi

Barcelona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04120935

Related Trials

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT0600424529 locations

Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

NCT067280722 locations

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

NCT073001505 locations

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT073188059 locations

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

NCT062058361 location